Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 6,454 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Clear all

Conditions: Kidney Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: radiofrequency ablation, thermal ablation therapy; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Transplantation
Interventions: AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Metastatic sRCC
Interventions: Avelumab, Gemcitabine; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypophosphatemia, Kidney Transplantation
Interventions: Dipyridamole 75 MG; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions: Venglustat GZ/SAR402671; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Renal Impairment
Interventions: ISIS 681257; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Social Psychology
Interventions: Intranasal vasopressin, Intranasal placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 30 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Migraine
Interventions: Nerivio (REN device); Device
Lead sponsor: Theranica; Industry
Eligibility: 8 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV Infections, Fanconi Syndrome, Kidney Disease, Renal Impairment
Interventions: Blood Draws; Procedure
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 7 more

Conditions: End Stage Renal Disease, Renal Transplant
Interventions: Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Tolera Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more

Conditions: Acute Kidney Injury
Interventions: SCD; Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Kidney Injury
Interventions: Data Inclusion; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Chronic Kidney Disease
Interventions: Nitrate-rich beetroot juice, Nitrate-depleted beetroot juice; Dietary Supplement
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 30 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Neoplasms
Interventions: BI 6727, IV infusion; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 19
States / cities: Beverly Hills, California • Los Angeles, California • Miami, Florida + 14 more

Conditions: Healthy Volunteers, Renal Impairment
Interventions: fezolinetant; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Garden Grove, California • Rialto, California • Clearwater, Florida + 4 more

Conditions: Renal Cell Carcinoma
Interventions: Cabozantinib tablets, Everolimus (Afinitor) tablets; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 59
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more

Conditions: Renal Transplantation
Interventions: Tisseelä fibrin sealant; Device
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: Not listed
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HCV Infection
Interventions: Voxilaprevir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 99 Years
Enrollment: 12,647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1976
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Renal Impairment
Interventions: LIK066; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions: Donor CD34+ and CD3+ cells; Biological
Lead sponsor: Jeffrey Veale, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Transplantation
Interventions: No intervention; Other
Lead sponsor: Paris Translational Research Center for Organ Transplantation; Other
Eligibility: 18 Years and older
Enrollment: 7,557 participants
Timeline: 2002 – 2020
U.S. locations: 3
States / cities: Baltimore, Maryland • Rochester, Minnesota • Richmond, Virginia

Conditions: Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions; Drug
Lead sponsor: LaTonya J. Hickson; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Avelumab/Gemcitabine in Sarcomatoid RCC

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Effect of Venglustat in Patients With Renal Impairment

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Vasopressin and the Social Brain

Nerivio Efficacy Under High-Frequency Use

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

I USE LR in the ED

Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Fibrin Sealant in Renal Transplantation

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Development and Validation of a Multidimensional Score to Predict Long-term Kidney Transplant Outcomes

Stem Cell Therapy for Chronic Kidney Disease